title: [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].
abstract: From October 2005 to September 2006, we collected the specimen from 366 patients with lower respiratory tract infections in 12 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 411 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, 406 strains were examined. The isolated bacteria were: Staphylococcus aureus 70, Streptococcus pneumoniae 85, Haemophilus influenzae 78, Pseudomonas aeruginosa (non-mucoid) 46, P. aeruginosa (mucoid) 14, Klebsiella pneumoniae 21, and Moraxella subgenus Branhamella catarrhalis 40. Of 70 S. aureus strains, those with 2 microg/ml or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 microg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 38 (54.3%) and 32 (45.7%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of 37 strains (97.4%) at 0.063 microg/ml or less. Against MRSA, arbekacin and vancomycin showed the most potent activity and inhibited the growth of all the strains at 1 microg/ml. Carbapenems showed the most potent activities against S. pneumoniae and in particular, panipenem inhibited the growth of all the strains at 0.063 microg/ml or less. Faropenem also had a preferable activity and inhibited the growth of all the strains at 0.25 microg/ml. In contrast, there were high-resistant strains (MIC: over 128 microg/ml) for erythromycin (38.1%) and clindamycin (22.6%). Against H. influenzae, levofloxacin showed the most potent activity and its MIC90 was 0.063 microg/ml or less. Meropenem showed the most potent activity against P. aeruginosa (mucoid) and its MIC90 was 0.5 microg/ml. Against P. aeruginosa (non-mucoid), arbekacin had the most potent activity and its MIC90 was 8 microg/ml. Against K. pneumoniae, cefozopran was the most potent activity and inhibited the growth of all the strains at 0.063 microg/ml or less. Also, all the antibacterial agents except ampicillin generally showed a potent activity against M. (B.) catarrhalis and the MIC90 of them were 2 microg/ml or less. The approximately half the number (53.6%) of the patients with respiratory infection were aged 70 years or older. Bacterial pneumonia and chronic bronchitis accounted for 44.3% and 29.8% of all the respiratory infection, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. aureus (15.4%), S. pneumoniae (23.4%), and H. influenzae (21.3%). S. aureus (25.4%) and S. pneumoniae (18.0%) also were frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from the patients were S. pneumoniae (22.0%) and H. influenzae (21.4%). The bacteria frequently isolated from the patients treated with macrolides were S. pneumoniae and P. aeruginosa, and their isolation frequencies were each 35.3%.
authors.affiliation: The First Department of Internal Medicine, Kyorin University School of Medicine.
authors.forename: Hajime
authors.initials: H
authors.lastname: Goto
authors.forename: Hideki
authors.initials: H
authors.lastname: Takeda
authors.forename: Shin
authors.initials: S
authors.lastname: Kawai
authors.forename: Suguru
authors.initials: S
authors.lastname: Watanabe
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Okazaki
authors.forename: Kaoru
authors.initials: K
authors.lastname: Shimada
authors.forename: Kunio
authors.initials: K
authors.lastname: Nakano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yokouchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Mori
authors.forename: Jun
authors.initials: J
authors.lastname: Igari
authors.forename: Toyoko
authors.initials: T
authors.lastname: Oguri
authors.forename: Makoto
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Kolichiro
authors.initials: K
authors.lastname: Kudo
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Tanaka
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawabata
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Nakamori
authors.forename: Midori
authors.initials: M
authors.lastname: Sumitomo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inoue
authors.forename: Toshihide
authors.initials: T
authors.lastname: Nakadate
authors.forename: Akira
authors.initials: A
authors.lastname: Suwabe
authors.forename: Yugo
authors.initials: Y
authors.lastname: Ashino
authors.forename: Nobuki
authors.initials: N
authors.lastname: Aoki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Honma
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Karasawa
authors.forename: Mikio
authors.initials: M
authors.lastname: Oka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kobashi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hirakata
authors.forename: Akira
authors.initials: A
authors.lastname: Kondou
authors.forename: Junichi
authors.initials: J
authors.lastname: Matsuda
authors.forename: Michiko
authors.initials: M
authors.lastname: Nakano
authors.forename: Satoru
authors.initials: S
authors.lastname: Oikawa
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D001991:Bronchitis / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D006193:Haemophilus influenzae / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000302:isolation & purification; D001936:Moraxella catarrhalis / Q000187:drug effects / Q000302:isolation & purification; D018410:Pneumonia, Bacterial / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013183:Sputum / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents